James R. Rigas

10.0k total citations · 2 hit papers
142 papers, 6.5k citations indexed

About

James R. Rigas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, James R. Rigas has authored 142 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pulmonary and Respiratory Medicine, 86 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in James R. Rigas's work include Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Research Studies (45 papers) and Lung Cancer Diagnosis and Treatment (33 papers). James R. Rigas is often cited by papers focused on Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Research Studies (45 papers) and Lung Cancer Diagnosis and Treatment (33 papers). James R. Rigas collaborates with scholars based in United States, United Kingdom and Canada. James R. Rigas's co-authors include Konstantin H. Dragnev, Mark G. Kris, Román Pérez-Soler, P. Santabárbara, Mark S. Huberman, Abraham Chachoua, Lisa A. Hammond, Philip Bonomi, Daniel D. Karp and Eric K. Rowinsky and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

James R. Rigas

142 papers receiving 6.3k citations

Hit Papers

Determinants of Tumor Response and Survival With Erlotini... 2004 2026 2011 2018 2004 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
    2004 893 citations James R. Rigas et al. Journal of Clinical Oncology profile →
  2. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
    2016 612 citations James R. Rigas et al. profile →

Peers

James R. Rigas
Hideo Kunitoh Japan
Neeltje Steeghs Netherlands
Rossana Berardi Italy
Albert Abad Spain
François Goldwasser France
Manuela Schmidinger Austria
Roscoe F. Morton United States
Apurva A. Desai United States
Daniel D. Karp United States
Glenwood Goss Canada
Hideo Kunitoh Japan
James R. Rigas
Citations per year, relative to James R. Rigas James R. Rigas (= 1×) peers Hideo Kunitoh

Countries citing papers authored by James R. Rigas

Since Specialization
Citations

This map shows the geographic impact of James R. Rigas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Rigas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Rigas more than expected).

Fields of papers citing papers by James R. Rigas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Rigas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Rigas. The network helps show where James R. Rigas may publish in the future.

Co-authorship network of co-authors of James R. Rigas

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Rigas. A scholar is included among the top collaborators of James R. Rigas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Rigas. James R. Rigas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schabath, Matthew B., Tapashi Dalvi, Hongyue Dai, et al.. (2019). <p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>. Cancer Management and Research. Volume 11. 9469–9481. 1 indexed citations
2.
Schabath, Matthew B., Tapashi Dalvi, Hongyue Dai, et al.. (2017). P1.01-042 Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S475–S476. 1 indexed citations
3.
Karve, Sudeep, Ralph M. Turner, Yen‐Wen Chen, et al.. (2017). P3.07-002 Complications and Costs of Diagnostic and Post-Progression Biopsies among Patients with Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1431–S1431. 2 indexed citations
4.
5.
Wood, Matthew D., Bassem I. Zaki, Stuart R. Gordon, et al.. (2013). Trimodality Therapy for Stage II–III Carcinoma of the Esophagus: A Dose-Ranging Study of Concurrent Capecitabine, Docetaxel, and Thoracic Radiotherapy. Journal of Thoracic Oncology. 8(4). 487–494. 7 indexed citations
6.
Dragnev, Konstantin H., Tian Ma, Fabrizio Galimberti, et al.. (2011). Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models. Cancer Prevention Research. 4(6). 818–828. 40 indexed citations
7.
Dragnev, Konstantin H., W. Jeffrey Petty, Sumit J. Shah, et al.. (2007). A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(6). 1794–1800. 63 indexed citations
8.
Black, Candice C., Mary Jo Turk, Peter DeLong, et al.. (2007). P1-160: Patterns of FoxP3 expression in tumor infiltrating lymphocytes. Journal of Thoracic Oncology. 2(8). S799–S799. 1 indexed citations
9.
Rigas, James R. & Karen Kelly. (2007). Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(6). S77–S85. 34 indexed citations
10.
Dragnev, Konstantin H., Qing Feng, Yan Ma, et al.. (2007). Uncovering Novel Targets for Cancer Chemoprevention. PubMed. 174. 235–243. 11 indexed citations
11.
Deitcher, Steven R., Craig M. Kessler, Geno J. Merli, et al.. (2006). Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period. Clinical and Applied Thrombosis/Hemostasis. 12(4). 389–396. 294 indexed citations
12.
Petty, W. Jeffrey, Konstantin H. Dragnev, Vincent A. Memoli, et al.. (2005). PROOF-OF-PRINCIPLE CLINICAL TRIAL OF BEXAROTENE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER. CHEST Journal. 128(4). 312S–312S. 1 indexed citations
13.
Hirsch, Fred R., Paul A. Bunn, Ethan Dmitrovsky, et al.. (2002). IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9–12, 2001. Lung Cancer. 37(3). 325–344. 14 indexed citations
14.
Petty, W. Jeffrey, Joerg Rathmann, Konstantin H. Dragnev, & James R. Rigas. (2002). The Role of Docetaxel in Nonplatinum-Based Combination Chemotherapy for non—small-Cell Lung Cancer. Clinical Lung Cancer. 3. S12–S16. 1 indexed citations
15.
Ornstein, Deborah L., et al.. (1999). Recent advances in cancer chemotherapy. Academic Radiology. 6(11). 696–705. 2 indexed citations
16.
17.
Bruno, René, Darcy A. Hille, A. Riva, et al.. (1998). Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.. Journal of Clinical Oncology. 16(1). 187–196. 348 indexed citations
18.
Nugent, William C., et al.. (1997). Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment. The Annals of Thoracic Surgery. 63(1). 193–197. 78 indexed citations
19.
Benedetti, Francesca, James R. Rigas, David G. Pfister, et al.. (1997). Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.. Journal of Clinical Oncology. 15(2). 790–795. 158 indexed citations
20.
Miller, Vincent A., James R. Rigas, Prudence A. Francis, et al.. (1995). Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75(4). 968–972. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideo Kunitoh Breakdown of academic impact, for papers by Neeltje Steeghs Breakdown of academic impact, for papers by Rossana Berardi Breakdown of academic impact, for papers by Albert Abad Breakdown of academic impact, for papers by François Goldwasser Breakdown of academic impact, for papers by Manuela Schmidinger Breakdown of academic impact, for papers by Roscoe F. Morton Breakdown of academic impact, for papers by Apurva A. Desai Breakdown of academic impact, for papers by Daniel D. Karp Breakdown of academic impact, for papers by Glenwood Goss
Rankless by CCL
2026